Breaking Finance News

AstraZeneca PLC (LON:AZN) stock price target held steady at 5,700.00GBX, reported today by Deutsche Bank

Only yesterday AstraZeneca PLC (LON:AZN) traded -0.02% lower at 5,322.00GBX. AstraZeneca PLC’s 50-day average is 4,885.88GBX and its two hundred day average is 4,910.79GBX. With the last close up 5.38% from the 200-day moving average, compared to the S&P 500 which has increased 0.03% over the date range. Volume of trade was up over the average, with 2,555,117 shares of AZN changing hands over the typical 2,517,920

AstraZeneca PLC (LON:AZN) had its target price hold steady to 5,700.00GBX by Deutsche Bank in a report released 6/05/2017. The new target price indicates a possible upside of 0.07% based on the company's last closing price.

Performance Chart

AstraZeneca PLC (LON:AZN)

With a market cap of 0 GBX, AstraZeneca PLC has 52 week low of 3,996.00GBX and a 52 week high of 5,520.00GBX with a price-earnings ratio of 16.97 .

A total of 29 brokerages have issued a ratings update on AstraZeneca PLC. 4 firms rating the stock a strong buy, 14 brokers rating the stock a buy, 13 equity analysts rating the company a hold, two equity analysts rating the company a underperform, and finally one analyst rating the company a sell with a 12-month price target of 61.96GBX.

General Company Details For AstraZeneca PLC (LON:AZN)

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVMD, it is expanding its portfolio into the cardiovascular-renal area with late-stage assets, such as ZS-9 and roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). The Company has approximately 40 projects in Phase I, including 29 new molecular entities (NMEs), and 11 oncology combination projects. It has approximately 40 projects in Phase II, including 25 NMEs; four significant additional indications for projects that have reached phase II, and seven oncology combination projects.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.